To address the global burden of sickle cell disease (SCD) and the need for novel therapies,
the American Society of Hematology partnered with the US Food and Drug Administration to …

Sickle cell disease (SCD) is a highly complex inherited disorder of hemoglobin structure.
Although the molecular lesion is a single-point mutation, the sickle gene is pleiotropic in …

This study aimed to comprehensively analyze inflammatory and autoimmune characteristics
of patients with sickle cell disease (SCD) at a steady-state condition (StSt) compared to …

Acute pain episodes are the most common complication in patients with sickle cell disease
(SCD). Classically attributed to vaso-occlusion, recent insights suggest that chronic pain …

Existing treatment for chronic pain in sickle cell disease (SCD) is opioid-dependent, which is
ineffective and carries risks. We conducted a scoping literature review to assess the size and …

Pain associated with sickle cell disease (SCD) is frequently treated with opioids which have
many side effects. There is a need for adjuvant non-opioid therapies that can improve pain …

Context Acute episodes of pain associated with sickle cell disease (SCD) account for over
100,000 hospitalizations and expenses of nearly one billion dollars annually in the US New …

Sickle cell disease (SCD) is a genetic blood disorder that impacts millions of individuals
worldwide. SCD is characterized by debilitating pain that can begin during infancy and may …

Context Sickle cell disease (SCD) is associated with recurrent pain that could lead to
abnormal sensory patterns (ASPs). Objectives The purpose of this study is to compare …

Objectives Over 50% of adults living with sickle cell disease (SCD) have chronic pain, but
the underlying mechanisms of chronic pain in this population remain unclear. Quantitative …